GPA TriMAR T cell therapy (Timmune Biotech)

N/A

Report date: 2024/12/23 11:19:27

Base Information

Drug NameGPA TriMAR T cell therapy (Timmune Biotech)
Drug Alias NameTCR-mimic-CAR-TGPA-TriMAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionGene transferenceImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTianjin Timmune Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Hainan Medical UniversityTianjin Timmune Biotech Inc
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A